Scientific Interchange & Workshop
Sponsored by Daiichi Sankyo. Content independently developed by OncLive®.
Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.
Funding from Daiichi Sankyo; Content Developed Independently by OncLive.
Funding from Daiichi Sankyo; Content Developed Independently by OncLive.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5